CompletedPhase 2NCT01484574
A Clinical Trial to Study the Efficacy and Safety of Different Doses of Bone Marrow Derived Mesenchymal Stem Cells in Patients With Critical Limb Ischemia Due to Buergers Disease
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stempeutics Research Pvt Ltd
- Principal Investigator
- Dr Anirban ChatterjeeAMRI Hospital
- Intervention
- Allogeneic Mesenchymal Stem Cells(biological)
- Enrollment
- 90 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2012 – 2016
Study locations (10)
- Division of Peripheral Vascular and Endovascular Sciences, Medanta - The Medicity, Gurgaon, Haryana, India
- Department of Vascular and Endovascular Surgery, M. S. Ramaiah Medical College and Hospitals, Bangalore, Karnataka, India
- Peripheral Vascular Surgery, Sri Jayadeva Institute of Cardiovascular Sciences & Research, Bangalore, Karnataka, India
- Department of Surgery, KMC, Mangalore, Mangalore, Karnataka, India
- Department of Surgical Disciplines, All India Institute of Medical Sciences, New Delhi, National Capital Territory of Delhi, India
- Department of Vascular Surgery, Madras Medical College, Chennai, Tamil Nadu, India
- Department of Vascular Surgery, Sri Ramchandra Medical College, Chennai, Tamil Nadu, India
- Department of Vascular Surgery, Stanley Medical College, Chennai, Tamil Nadu, India
- Department of Vascular Surgery, AMRI Hospital, Kolkata, West Bengal, India
- Nightingale Hospital, Kolkata, West Bengal, India
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01484574 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07215923A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy SmokersAntidote Therapeutics, Inc
- ENROLLING BY INVITATIONNCT07023965Follow-up Study Using Gene Therapy for Critical Limb Ischemia (NL003-CLI-III-L)Beijing Northland Biotech. Co., Ltd.
- RECRUITINGPHASE4NCT05854615Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's DiseaseCell Biopeutics Resources Sdn Bhd